Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Zynerba Pharma CS (NQ: ZYNE )

0.6302 +0.0196 (+3.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 373,917
Open 0.6400
Bid (Size) 0.6200 (40)
Ask (Size) 0.6380 (12)
Prev. Close 0.6106
Today's Range 0.6011 - 0.6400
52wk Range 0.4900 - 2.940
Shares Outstanding 47,062,711
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga

Performance

YTD
+14.77%
+14.77%
1 Month
+14.77%
+14.77%
3 Month
-12.47%
-12.47%
6 Month
-46.59%
-46.59%
1 Year
-75.76%
-75.76%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
What's The Role Of The Endocannabinoid System In Fragile X Syndrome? How Can Cannabidiol Treatment Help? New Paper
Via Benzinga
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Zynerba Pharmaceuticals Announces Update on RECONNECT, the Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
CBD-Based Zygel Helps With Anxiety-Related & Behavioral Symptoms In 22q11.2 Deletion Syndrome, Phase 2 Trial Reveals
Via Benzinga
Zynerba Pharmaceuticals Announces Positive Long-Term Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
Zynerba Pharmaceuticals Announces Poster Presentation at the Annual Meeting of the American College of Neuropsychopharmacology
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabis Legalization In Germany And Thailand, Gray Market In Brooklyn, Craft Weed Companies In Oregon
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details
Via Benzinga
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
A Comparison Of 5 Psychedelic ETFs And Indices
Via Talk Markets
The Psychedelic Drug Stocks Index Continued To Plummet Last Week
Via Talk Markets
Zynerba Pharmaceuticals Announces Issuance of New U.S. Patent for Zygel™ for the Treatment of 22q11.2 Deletion Syndrome
From Zynerba Pharmaceuticals, Inc.
Via Globe NewsWire
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
Via Talk Markets
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.